University of Thessaly (UTH)
CD8 T-κυτταρική απάντηση έναντι των αντιγόνων της σαρβινίνης και της τελομεράσης στον καρκίνο του πνεύμονα
Abstract
dc:descriptionOBJECTIVE Cytolytic CD8+ T cells are one of the major effector mechanisms against tumor specific immune response. Their study, using modern techniques of cellular immunity, is a subject of interest regarding the understanding of failure of immunosurveillance to control tumor growth, and their involvement in cancer immunotherapy. The purpose of this study was to detect CTL clones against epitopes of survivin, survivin-2B and hTERT in peripheral blood and TILs in patients with lung cancer, and to quantitatively and qualitatively characterize these clones in comparison with the corresponding clones, which may be detected in healthy subjects by using highly sensitive techniques. MATERIAL Peripheral blood was collected from 20 patients with primary lung cancer (at diagnosis) (17 men and 3 women, mean age 56 ± 2.3 years) and 5 healthy donors (5 men, mean age 67.1 ± 9.9 years). In 5 out of 9 patients with lung cancer, peripheral blood also collected 3 weeks after 3-6 cycles of platinum. Also, tumor tissue was collected and TILs were isolated from patients who underwent surgery. METHODS Cytolytic CD8+ T cells against specific peptide of survivin, survivin-2B and telomerase were detected after in vitro amplification of several hundred microcultures under limiting dilution conditions. The detection of these cells was achieved by HLA-multimer flow cytometric technology. The frequency of antigen specific CD8 T cells was estimated by the use of Poisson distribution analysis for rare events, corrected by Bernoulli. CD8 lines were isolated and characterized phenotypically on the basis of extracellular markers that define the differentiation stage. CD8 clones from patients and normal individuals were isolated by magnetic sorting, and characterized phenotypically and functionally regarding their lytic capacity, cytokine production and affinity of their TCR. RESULTS (a) in peripheral blood, anti-survivin or anti-survivin-2B specific CTL clones were not detected in patients, and in none of the healthy individuals, while (B) in both groups specific CTLs against peptides of telomerase, hTERT.A2 and hTERT.A24, were detected, however, the CTL frequency in patients showed higher variation. (c) The frequency of circulating peptide-specific pCTLs appeared to be unaffected by radio- and chemotherapy. (d) Compared to CTLs of healthy individuals, specific CTL clones of cancer patients showed similar qualitative and quantitative characteristics. (e) Anti-EBV CD8 T cells were detected in cancer patients at similar levels to those of healthy individuals. (f) In TILs, specific CD8 T cell response against tumor antigens was undetectable, however, specific CTL clones against viral peptides were identified. CONCLUSION The absence of detectable CD8 T cell responses against peptides of surviving, opposed to the presence pCTLs against peptides of hTERT, raises important questions regarding the immunogenicity of survivin and the use of its peptides in cancer immunotherapy, including lung cancer. The variation in frequency of detectable specific cytolytic clones and the pCTL functional differences between patients and normal subjects could represent key factors in understanding the immune response in clinical trials and the design of improved cancer immunotherapy.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Σούκου, Φωτεινή
- Soukou, Foteini
Subjects
dc:subject × 20- CD8 T απάντηση
- HLA-πολυμερή
- Συχνότητα ανίχνευσης
- Σαρβιβίνη
- Τελομεράση
- Αντιγόνα των όγκων
- Καρκίνος πνεύμονα
- Αντιγονοειδικά CD8 T-κύτταρα
- CD8 T cell response
- HLA-multimers
- Precursor frequency
- Survivin
- Telomerase
- Tumor antigens
- Lung cancer
- Peptide-specific CD8 T-cells
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29804